| abstract |
Disclosed is a polymer having controlled end group stoichiometry in the pharmaceutical use of dendritic polymers. A polymer having controlled end group stoichiometry, wherein the first end group is a residue of a surface layer, at least one subsurface layer, and a pharmaceutically active agent, derivative or precursor thereof. And a polymer comprising at least two end groups comprising a second end group selected to modify the pharmacokinetics of the pharmaceutically active agent and / or polymer (in this case, end group stoichiometry is defined as end group stoichiometry). Number and type). The second end group is selected from one or more of the following: a pharmaceutically active agent and / or a moiety that modifies the plasma half-life of the macromolecule; a pharmaceutically active agent for one or more cell types or tissue types and / or A moiety that facilitates targeting of the macromolecule; and a moiety that facilitates uptake of the pharmaceutically active agent and / or macromolecule into one or more cell types or tissue types. [Selection figure] None |